Cargando…
Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada
BACKGROUND: Timeliness in the administration of recommended vaccines is often evaluated using vaccine delays and provides more information regarding the susceptibility of children to vaccine-preventable diseases compared with vaccine coverage at a given age. The importance of on-time administration...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288945/ https://www.ncbi.nlm.nih.gov/pubmed/30537969 http://dx.doi.org/10.1186/s12889-018-6235-6 |
_version_ | 1783379892259258368 |
---|---|
author | Kiely, Marilou Boulianne, Nicole Talbot, Denis Ouakki, Manale Guay, Maryse Landry, Monique Sauvageau, Chantal De Serres, Gaston |
author_facet | Kiely, Marilou Boulianne, Nicole Talbot, Denis Ouakki, Manale Guay, Maryse Landry, Monique Sauvageau, Chantal De Serres, Gaston |
author_sort | Kiely, Marilou |
collection | PubMed |
description | BACKGROUND: Timeliness in the administration of recommended vaccines is often evaluated using vaccine delays and provides more information regarding the susceptibility of children to vaccine-preventable diseases compared with vaccine coverage at a given age. The importance of on-time administration of vaccines scheduled at the first visit is well documented, but data are scarce about the impact of vaccine delays at other visits on vaccination status by 24 months of age. Using vaccine delays for the first three doses of DTaP-containing vaccines and for the first dose of measles-containing vaccines as markers of timeliness at the 2, 4, 6 and 12 month visits, we estimated the proportion of incomplete vaccination status by 24 months of age attributable to a vaccine delay at each of these visits. METHODS: We used the data from six cross-sectional coverage surveys conducted in the Province of Quebec from 2006 to 2016 which included 7183 children randomly selected from the universal health insurance database. A vaccine dose was considered delayed if received 30 days or more after the recommended age. The impact of new vaccine delays at each visit on incomplete vaccination status by 24 months of age was estimated with the attributable risk in the population. RESULTS: The proportion of children with vaccine delay was 5.4% at 2 months, 13.3% at 4 months, 23.1% at 6 months and 23.6% at 12 months. Overall, 72.5% of all 2-year-old children with an incomplete status by 24 months were attributable with a vaccine delay, of which 16.1% were attributable with a first vaccine delay at 2 months, 10.6% at 4 months, 14.0% at 6 months and 31.8% at 12 months. CONCLUSIONS: While great emphasis has been put on vaccine delays at the first vaccination visit, the prevalence of vaccine delays was greater with later visits and most children with an incomplete vaccination status by 24 months had a vaccine delay occurring during these later visits. Interventions to improve timeliness should address vaccine delays at each visit and not only focus on the first visit. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12889-018-6235-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6288945 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62889452018-12-14 Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada Kiely, Marilou Boulianne, Nicole Talbot, Denis Ouakki, Manale Guay, Maryse Landry, Monique Sauvageau, Chantal De Serres, Gaston BMC Public Health Research Article BACKGROUND: Timeliness in the administration of recommended vaccines is often evaluated using vaccine delays and provides more information regarding the susceptibility of children to vaccine-preventable diseases compared with vaccine coverage at a given age. The importance of on-time administration of vaccines scheduled at the first visit is well documented, but data are scarce about the impact of vaccine delays at other visits on vaccination status by 24 months of age. Using vaccine delays for the first three doses of DTaP-containing vaccines and for the first dose of measles-containing vaccines as markers of timeliness at the 2, 4, 6 and 12 month visits, we estimated the proportion of incomplete vaccination status by 24 months of age attributable to a vaccine delay at each of these visits. METHODS: We used the data from six cross-sectional coverage surveys conducted in the Province of Quebec from 2006 to 2016 which included 7183 children randomly selected from the universal health insurance database. A vaccine dose was considered delayed if received 30 days or more after the recommended age. The impact of new vaccine delays at each visit on incomplete vaccination status by 24 months of age was estimated with the attributable risk in the population. RESULTS: The proportion of children with vaccine delay was 5.4% at 2 months, 13.3% at 4 months, 23.1% at 6 months and 23.6% at 12 months. Overall, 72.5% of all 2-year-old children with an incomplete status by 24 months were attributable with a vaccine delay, of which 16.1% were attributable with a first vaccine delay at 2 months, 10.6% at 4 months, 14.0% at 6 months and 31.8% at 12 months. CONCLUSIONS: While great emphasis has been put on vaccine delays at the first vaccination visit, the prevalence of vaccine delays was greater with later visits and most children with an incomplete vaccination status by 24 months had a vaccine delay occurring during these later visits. Interventions to improve timeliness should address vaccine delays at each visit and not only focus on the first visit. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12889-018-6235-6) contains supplementary material, which is available to authorized users. BioMed Central 2018-12-11 /pmc/articles/PMC6288945/ /pubmed/30537969 http://dx.doi.org/10.1186/s12889-018-6235-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Kiely, Marilou Boulianne, Nicole Talbot, Denis Ouakki, Manale Guay, Maryse Landry, Monique Sauvageau, Chantal De Serres, Gaston Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada |
title | Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada |
title_full | Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada |
title_fullStr | Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada |
title_full_unstemmed | Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada |
title_short | Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada |
title_sort | impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in quebec, canada |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288945/ https://www.ncbi.nlm.nih.gov/pubmed/30537969 http://dx.doi.org/10.1186/s12889-018-6235-6 |
work_keys_str_mv | AT kielymarilou impactofvaccinedelaysatthe246and12monthvisitsonincompletevaccinationstatusby24monthsofageinquebeccanada AT bouliannenicole impactofvaccinedelaysatthe246and12monthvisitsonincompletevaccinationstatusby24monthsofageinquebeccanada AT talbotdenis impactofvaccinedelaysatthe246and12monthvisitsonincompletevaccinationstatusby24monthsofageinquebeccanada AT ouakkimanale impactofvaccinedelaysatthe246and12monthvisitsonincompletevaccinationstatusby24monthsofageinquebeccanada AT guaymaryse impactofvaccinedelaysatthe246and12monthvisitsonincompletevaccinationstatusby24monthsofageinquebeccanada AT landrymonique impactofvaccinedelaysatthe246and12monthvisitsonincompletevaccinationstatusby24monthsofageinquebeccanada AT sauvageauchantal impactofvaccinedelaysatthe246and12monthvisitsonincompletevaccinationstatusby24monthsofageinquebeccanada AT deserresgaston impactofvaccinedelaysatthe246and12monthvisitsonincompletevaccinationstatusby24monthsofageinquebeccanada |